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INTRODUCTION
Patients who suffered from malignant ovarian
tumor have high risks of developing thromboem-
bolism. The incidence of deep vein thrombosis
(DVT) malignant ovarian neoplasm varies from 5%
to 29%.1-5 Release of tissue and pro-coagulant
factors by cancer cells may lead to coagulation
activation and hyperviscosity6 release of various
cytokines by cancer cells could lead to endothelial
injury. Several factors related to the treatment such
as surgery and immobilization may cause venous
stasis.7,8 DVT has been associated with poor prog-
nosis.9 It is estimated that patients with DVT had
a 2.2-fold increased risk in mortality compared to
those without DVT. DVT is the source of pulmonary
Abstract
Objective: To investigate the clinical and laboratory predictors of
symptomatic deep vein thrombosis (DVT) in ovarian malignant
tumor.
Methods: One hundred sixteen patients with suspected ovarian
malignant tumor were recruited. Age, body mass index (BMI);
D-dimer, fibrinogen, thrombocyte level, comorbid, tumor diameter,
staging, distant metastasis, ascites, histopathology, length of surgery,
blood loss and transfusion were recorded.
Results: Incidence of symptomatic DVT was 16.5% and 88.2% cases
occurred before surgery. No case of symptomatic DVT during post-
operative care was found. Predictors of DVT were distant metastasis
(OR 28.99; 95% CI 3.83-219.52, BMI  22.7 kg/m2 (OR 15.52, 95%
CI 2.24-107.37), D-Dimer  1700 mg/ml (OR 13.30, 95% CI 2.40-
73.84), advanced stage (OR 6.66; 95% CI 1.05-42.27), epithelial
tumor (OR 6.5; 95% CI 0.34-125.75), tumor’s diameter  18.25 cm
(OR 2.36, 95% CI 0.48-11.54), and comorbidity (OR 2.49, 95% CI
0.53-11.66). Prediction score of DVT were score 3 for distant me-
tastasis, BMI  22.7 kg/m2, D-Dimer  1700 mg/ml, score 2 for
advanced stage, score 1 for tumor diameter  18.25 cm, comorbid,
epithelial tumor and score 0 for the absence of variables or its value
less than the cut off. Total score  8 of 14 is the least score which has
a good predictive value for DVT with AUC 0.92, 95% CI 0.86-0.92,
probability 86.46%.
Conclusion: Distant metastasis and D-dimer are independently
associated with the development of DVT in ovarian malignant
tumor.
[Indones J Obstet Gynecol 2017; 5-3: 180-184]
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Abstrak
Tujuan: Untuk mengetahui prediktor klinis dan laboratorium
dari thrombosis vena dalam simptomatik pada tumor ganasovarium.
Metode: Seratus enam belas pasien yang diduga menderita tumorganas ovarium direkrut ke dalam penelitian. Usia, indeks massa tubuh
(IMT), kadar D-dimer, fibrinogen, trombosit, komorbid, karakteristik
tumor (diameter, stadium, metastasis jauh, asites, histopatologi), lamapembedahan, jumlah perdarahan serta transfusi durante operasi di-
dokumentasikan.
Hasil: Insiden TVD simptomatik adalah 16,5% dan 88,2% kasus
terjadi sebelum pembedahan. Tidak ditemukan kasus TVD selamaperawatan pasca-operasi. Prediktor TVD adalah metastasis jauh
(OR 28,99; 95% CI 3,83-219,52, IMT  22,7 kg/m2 (OR 15,52, 95% CI
2,24-107,37), D-dimer  1700 mg/ml (OR 13,30, 95% CI 2,40-73,84),stadium lanjut (OR 6,66; 95% CI 1,05-42,27), tumor epithelial (OR
6,5; 95% CI 0,34-125,75), diameter tumor 18,25 cm (OR 2,36, 95%CI 0,48-11,54), dan adanya komorbid (OR 2,49, 95% CI 0,53-11,66).
Skor prediksi kejadian TVD adalah skor 3 untuk metastasis jauh,
IMT  22,7 kg/m2, kadar D-Dimer  1700 mg/ml, skor 2 untuktumor stadium lanjut, skor 1 untuk diameter tumor  18,25 cm,
adanya komorbid, tumor epitelial dan skor 0 jika tidak memiliki
faktor prediktor atau nilai faktor prediktor kurang dari titik potong.Skor total 8 dari 14 adalah skor minimum yang masih memiliki
nilai prediksi yang baik kejadian TVD dengan AUC 0,92, 95% CI0,86-0,92 dan probabilitas 86,46%.
Kesimpulan: Metastasis jauh dan D-dimer berkaitan secara inde-penden dengan terjadinya DVT pada tumor ganas ovarium.
[Maj Obstet Ginekol Indones 2017; 5-3: 180-184]
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embolism, a fatal condition that could lead to
mortality.10 Therefore, early detection of patients
who are at high risk of DVT is crucial for proper
prophylaxis.
METHODS
This was a prospective study of 116 subjects
suspected with malignant ovarian tumor. The
study was conducted at Dr. Cipto Mangunkusumo
Hospital. The protocol of this research was
approved by the Ethics Committee of Dr. Cipto
Mangunkusumo Hospital. Pretreatment peripheral
blood samples, D-dimer, fibrinogen levels were
measured in all patients. Patients who had sign and
symptoms of DVT underwent venous Duplex
ultrasonography. The cut off level for each nume-
rical variable as predictor of DVT was determined
using RO analysis. The 2 test or Fisher Exact Test
was used to evaluate the risk of DVT associated
with each categorical variable. Multivariate logistic
regression was performed to determine the
strength of each variable as a predictor factor for
DVT and create the prediction score of DVT in
ovarian malignancy. A p-value less than 0.05 was
considered statistically significant. All statistical
analyses were performed using SPSS.
RESULT
Characteristics of the subjects
A total of 113 subjects were involved in this study.
Thirteen patients were withdrawn (6 patients had
benign ovarian tumor from histopathology and 7
patients had incomplete data. Characteristics of the
subjects are shown in Table 1.
Incidence of deep vein thrombosis
Venous ultrasonography revealed DVT in 17 of 103
patients (16.5%) and 15 cases (88.2%) occurred
before initial treatment for ovarian malignancy. No
symptomatic DVT was observed during hospitali-
zation with mean length of stay 8.8 days.
Table 1. Characteristic of the Subjects
Characteristics TVD (+)  TVD (­) Value p
Age (years) 50.35  10.90 46.1  12.05 0.250
BMI (kg/m2) 23.31  5.04 22.14  3.80 0.278
Tumor’s diameter 20.97  9.28 17.47  7.21 0.085
Length of surgery 4.5  2.40 4.5  1.75 0.998
Bleeding 1296  1171 901  1011 0.234
Transfusion 367.09  450.604 279.81  532.25 0.604
Thrombocyte (per mm3) 342058.8  125801.1 370732.6  143790 0.446
D-Dimer (mg/ml) 3452.94  3747.519 1172.74  1847 0.025
Fibrinogen (mg/ml)
Comorbid
Yes 10 (58.82%) 36 (41.86%) 0.308
None 9 (52.94%) 50 (58.14%)
Distant Metastasis
Yes 8 (47.06%) 7 (8.14%) 0.0002
None 6 (35.3%) 79 (91.86%)
Bilateral tumor
Bilateral 7 (41.18%) 24 (27.91%) 0.566
Unilateral 11 (64.7%) 62 (72.09%)
Ascites
Yes 10 (0.58%) 38 (44.19%) 0.401
No 7 (41.18%) 48  (55.81%)
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Predictor  factors and scoring of DVT
The cut off value for each numerical variable as a
predictor of TVD was age  50 years, BMI  22.76
kg/m2, tumor diameter  18.25 cm, thrombocyte
count 326.500/mm3, fibrinogen  399.7 mg/dl, D-
dimer  1700 mg/ml. Through multivariate logistic
regression with stepwise and backward selection,
we generated the prediction model of DVT. The OR,
CI and prediction value for each parameter of DVT
were presented in Table 2. A total score  8 of 14
is the least score which still had a high prediction
value of DVT with sensitivity of 64.7%, specificity
of 90.7%, negative prediction value 92.86%, posi-
tive prediction value of 57.89%. This prognostic
model had a good discrimination level with AUC
0.921 (95% CI 0.862-0.980) and good calibration
with p<0.05 based on Hosmer and Lameshow
analysis (Figure 1).
Table 2. The OR, CIs and Prediction Score of DVT in Ovarian Malignant Tumor
Variable Adjusted OR 95% CI Prediction Score
Distant Metastasis
Yes 28.998 3.83-219.52 3
No 0
Body Mass Index
 22.76 kg/m2 15.519 2.24-107.37 3
< 22.76 kg/m2 0
D-dimer
 1700 mg/ml 13.305 2.39-73.84 3
< 1700 mg/ml 0
Stage of the tumor
Advance stage (III and IV) 6,660 1.5-42.27 2
Early Stage (I and II) 0
Histopathology
Epithelial tumor 6.500 0.34-125.75 1
Non epithelial 0
Tumor’s diameter
 18.25 cm 2,359 0.48-11.54 1
< 18.25 cm 0
Presence of comorbidity
Yes 2,495 0.53-11.66 1
None 0
Table 3. Sensitivity, Specificity, Positive and Negative Predictive Values at each Prediction Score of DVT. PPV, Positive
predictive Value; NPV: Negative Predictive Value
Total score Sensitivity (%) Specificity (%) PPV NPV
1 100.0 2.3 16.83 100
2 100.0 5.8 17.35 100
3 100.0 19.8 19.77 100
4 100.0 31.4 22.37 100
5 100.0 45.3 26.56 100
6 100.0 64.0 35.42 100
7 82.4 81.4 46.67 95.89
8 64.7 90.7 57.89 92.86
9 64.7 96.5 78.57 93.25
10 41.2 98.8 87.5 89.47
11 29.4 100.0 100 87.75
12 11.8 100.0 100 85.15
13 5.9 100.0 100 85.15
14 0.0 100.0 100 84.16
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DISCUSSION
Ovarian malignancy is one of the tumors which
have high incidence of symptomatic and asympto-
matic DVT ranging from 5-35%. Our study found
the incidence of symptomatic DVT of 16.5%.
Factors related to cancer treatment such as surgery
was shown to increase the risk of DVT by 2 to 5
fold, and most of DVT cases occurred within the
first 2 week post-surgery.11,12 In contrast with
previous study, this study found that most of DVT
cases (88.2%) occurred before initial treatment,
and no DVT cases occurred during post-operative
hospitalization with mean of length of stay of 8.8
days. Obstruction of the venous return of the lower
extremities due to massive tumor within pelvic
cavity, massive ascites leading to intravascular
hypovolemic, massive cancer cells before any
treatment which release massive tissue factor are
the possible explanation for DVT occurrence before
treatment.4,13
Numerous factors including advanced age14-17,
higher body mass index3,15-17, presence of ascites1-
3,14, several specific histopathology subtypes2,14,
advanced tumor stage3,15-18, presence of metasta-
sis2,14, surgery14, chemotherapy1, and higher D-
dimer and fibrinogen levels4-5,12 were reported as
predictors of DVT in malignant tumor. We found
that prediction models derived from parameters
including presence of distant metastasis, BMI, D-
dimer level, tumor stage, tumor diameter, histology
subtype and presence of comorbid was highly
predictive of deep vein thrombosis in ovarian ma-
lignant tumor. Score 8 of 14 is the least score which
still had a good prediction for DVT with an area
under the receiver operator characteristics curve
of 0.92. The application of prediction model may
help to stratify individual risk of DVT which then
can be used for selective prevention of DVT. Our
study found that distant metastasis was the
strongest predictor of DVT in ovarian malignant
tumor, in accordance with previous study2,14
followed by higher D-dimer level. Cut off the Dimer
as predictor of DVT in our study was 1700 mg/ml
with its area under curve of 0.76, sensitivity
79.2%, specificity 81.2%, NPV 42.86% and PPV
92.86%. Correlation of D-dimer level with DVT was
extensively investigated and the cut off D-dimer as
predictor for DVT found in our study was almost
similar with cut off reported in previous study.5,19
High D-dimer levels was reported associated with
poor prognosis in cancer patients as it associated
with more advanced stage and higher tendency
for metastasis.4-5,12,20 Higher BMI was another
independent predictor of DVT in our study, which
is in line with previous studies.3,15-17 Advanced
stage (stage III and IV) was another predictor of
DVT in our study. Advanced stage was commonly
associated with larger tumor size. As reported by
previous studies, we found that larger tumor
diameter12 with cut off value of 18.25 cm caused a
2.8 fold increased risk of DVT.
Presence of other clinical disorders (comorbid)
which influence any factor contributed in
thrombus formation such as vascular injury,
activate coagulation system or vascular stasis will
increase the risk of DVT.1,14 In our study, the
presence of comorbidity increases the risk of DVT
up to 1.77 fold. The most comorbidities found in
our study were hypertension, diabetes mellitus,
renal disease and cardiac disorder.
Our study has several limitations. Firstly, the
evidence of DVT by Duplex ultrasonography was
only confirmed in symptomatic patients therefore
the incidence if DVT found in this case was only
symptomatic DVT. Another weakness of our study
is the small sample size. Further studies with larger
sample sizes are required to be conducted in the
future for a better understanding of the predictors
of DVT in malignant ovarian tumors.
Figure  1. Receiver Operator Curves for prediction of
deep vein thrombosis
Prediction model of DVT
AUC 0.92(CI 95%: 0.86-0.98)
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CONCLUSION
Distant metastasis and D-dimer are independently
associated with the development of DVT in ovarian
malignant tumor.
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